Jingsong Yang

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 601 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

Li Liu, Patrick A. Mayes, Stephen D. Eastman et al. · Clinical Cancer Research · 2015 · 447 citations

Medicine, Immunology, Oncology +17

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

Alastair J. King, Marc R. Arnone, Maureen R. Bleam et al. · PLoS ONE · 2013 · 217 citations · Full text

Medicine, Oncology, Pharmacology +16

Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction

Aidan G. Gilmartin, Thomas Faitg, Mark C. Richter et al. · Nature Chemical Biology · 2014 · 208 citations

Life Sciences, Biochemistry, Molecular Biology +14

The dynamic processivity of the T4 DNA polymerase during replication

Jingsong Yang, Zhihao Zhuang, Rosa Maria Roccasecca et al. · Proceedings of the National Academy of Sciences · 2004 · 130 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15